{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:09:09Z","timestamp":1789729749071,"version":"4.0.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"41","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100014588","name":"Sanofi Pasteur","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014588","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.vaccine.2012.07.043","type":"journal-article","created":{"date-parts":[[2012,7,31]],"date-time":"2012-07-31T08:46:27Z","timestamp":1343724387000},"page":"5935-5941","source":"Crossref","is-referenced-by-count":65,"title":["Immunogenicity and safety of tetravalent dengue vaccine in 2\u201311 year-olds previously vaccinated against yellow fever: Randomized, controlled, phase II study in Piura, Peru"],"prefix":"10.1016","volume":"30","author":[{"given":"Claudio F.","family":"Lanata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana I.","family":"Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Terrones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Valladolid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betzana","family":"Zambrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Saville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Crevat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2012.07.043_bib0005","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S1473-3099(11)70147-5","article-title":"The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the informal WHO working group on geographic risk for yellow fever","volume":"11","author":"Jentes","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2012.07.043_bib0010","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1038\/nrmicro2460","article-title":"Dengue: a continuing global threat","volume":"8","author":"Guzman","year":"2010","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2012.07.043_bib0015","doi-asserted-by":"crossref","first-page":"128","DOI":"10.4269\/ajtmh.2010.09-0346","article-title":"The epidemiology of dengue in the Americas over the last three decades: a worrisome reality","volume":"82","author":"San Mart\u00edn","year":"2010","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2012.07.043_bib0020","series-title":"Vaccines","first-page":"959","article-title":"Yellow fever vaccine","author":"Monath","year":"2008"},{"key":"10.1016\/j.vaccine.2012.07.043_bib0025","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.biotechadv.2010.11.008","article-title":"Review of dengue virus and the development of a vaccine","volume":"29","author":"Murrell","year":"2011","journal-title":"Biotechnol Adv"},{"key":"10.1016\/j.vaccine.2012.07.043_bib0030","doi-asserted-by":"crossref","first-page":"7276","DOI":"10.1016\/j.vaccine.2011.07.017","article-title":"Next generation dengue vaccines: a review of candidates in preclinical development","volume":"29","author":"Schmitz","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.07.043_bib0035","doi-asserted-by":"crossref","first-page":"7229","DOI":"10.1016\/j.vaccine.2011.06.094","article-title":"From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine","volume":"29","author":"Guy","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.07.043_bib0040","doi-asserted-by":"crossref","first-page":"5477","DOI":"10.1128\/JVI.74.12.5477-5485.2000","article-title":"Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates","volume":"74","author":"Guirakhoo","year":"2000","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2012.07.043_bib0045","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1086\/649916","article-title":"A novel tetravalent dengue vaccine is well-tolerated and immunogenic against all four serotypes in flavivirus-na\u00efve adults","volume":"201","author":"Morrison","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2012.07.043_bib0050","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1016\/j.vaccine.2011.03.057","article-title":"Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines","volume":"29","author":"Capeding","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.07.043_bib0055","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1097\/INF.0b013e3181fe05af","article-title":"Live-attenuated tetravalent dengue vaccine in dengue-na\u00efve children, adolescents and adults in Mexico city: randomized controlled phase 1 trial of safety and immunogenicity","volume":"30","author":"Poo","year":"2011","journal-title":"Ped Infect Dis J"},{"key":"10.1016\/j.vaccine.2012.07.043_bib0060","first-page":"4201","article-title":"Dengue 2 vaccine: dose response in volunteers in relation to yellow fever immune status","volume":"135","author":"Scott","year":"1983","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2012.07.043_bib0065","doi-asserted-by":"crossref","first-page":"60","DOI":"10.4161\/hv.2.2.2555","article-title":"Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes","volume":"2","author":"Guirakhoo","year":"2006","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2012.07.043_bib0070","series-title":"Guidelines on the quality, safety and efficacy of dengue tetravalent vaccines (live, attenuated)","author":"World Health Organization","year":"2011"},{"key":"10.1016\/j.vaccine.2012.07.043_bib0075","series-title":"Guidelines for plaque reduction neutralization testing of human antibodies to dengue viruses","author":"World Health Organization","year":"2007"},{"key":"10.1016\/j.vaccine.2012.07.043_bib0080","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jviromet.2008.03.026","article-title":"Standardized quantitative RT-PCR assays for quantitation of yellow fever and chimeric yellow fever-dengue vaccines","volume":"151","author":"Mantel","year":"2008","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2012.07.043_bib0085","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.3201\/eid1511.090663","article-title":"Dengue virus serotype 4, Northeastern Peru, 2008","volume":"15","author":"Forshey","year":"2009","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2012.07.043_bib0095","doi-asserted-by":"crossref","first-page":"724","DOI":"10.4269\/ajtmh.2011.10-0436","article-title":"Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity and safety of a tetravalent dengue vaccine in humans","volume":"85","author":"Qiao","year":"2011","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2012.07.043_bib0100","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1086\/648592","article-title":"Trends in patterns of dengue transmission over 4 years in a pediatric cohort study in Nicaragua","volume":"201","author":"Balmaseda","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2012.07.043_bib0105","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.vaccine.2009.09.098","article-title":"Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses","volume":"28","author":"Guy","year":"2010","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12010560?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12010560?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T04:39:30Z","timestamp":1588826370000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X12010560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":20,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S0264410X12010560"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2012.07.043","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}